CPX-351 is beginning to replace traditional 3+7 chemotherapy for secondary or high-risk AML. Learn what you need to know to use it effectively in the clinic.
Here are my thoughts on how best to apply the recently approved targeted agents gemtuzumab ozogamicin, midostaurin, and enasidenib to improve outcomes for your patients with acute myeloid leukemia.
What are some of the most clinically important AML abstracts to watch for at ASH this year? Read on for a few expert selections.
Watch this on-demand Webcast from the CCO AML satellite symposium at ASH 2017, featuring expert faculty Jeffrey E. Lancet, MD; Gail J. Roboz, MD; B. Douglas Smith, MD; and Roland B. Walter, MD, PhD, MS, as they discuss the most clinically relevant advances in treatment strategies for patients with AML.
Download this guide for a quick overview of phase III multicenter clinical trials in acute myeloid leukemia currently recruiting patients to find a study that may offer your patient an opportunity for the latest individualized treatment in AML.
Download this guide for a quick overview of current approaches in the use of molecular analysis to individualize treatment strategies in patients with acute myeloid leukemia.
In this downloadable slideset, B. Douglas Smith, MD, explores current strategies for diagnosing and treating patients with acute myeloid leukemia based on patient medical history and cytogenetic and molecular markers.
In this downloadable slideset, Jeffrey E. Lancet, MD, explores current strategies for treating patients with newly diagnosed acute myeloid leukemia based on patient medical history and cytogenetic and molecular markers.
In this downloadable slideset, Gail J. Roboz, MD, explores optimal treatment approaches for patients with relapsed/refractory acute myeloid leukemia.
In this downloadable slideset, Roland B. Walter, MD, PhD, MS, examines FLT3, IDH1, and BCL2 inhibitors as well as other promising investigational treatments in clinical trial that may provide therapeutic advances for the management of patients with acute myeloid leukemia.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.